AAAAAA

   
Results: 1-9 |
Results: 9
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001.
Authors: Munster, PN Basso, A Solit, D Norton, L Rosen, N
Citation: Pn. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001., CLIN CANC R, 7(8), 2001, pp. 2228-2236
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
Authors: Chiosis, G Timaul, MN Lucas, B Munster, PN Zheng, FF Sepp-Lorenzino, L Rosen, N
Citation: G. Chiosis et al., A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells, CHEM BIOL, 8(3), 2001, pp. 289-299
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
Authors: Munster, PN Srethapakdi, M Moasser, MM Rosen, N
Citation: Pn. Munster et al., Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells, CANCER RES, 61(7), 2001, pp. 2945-2952
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
Authors: Munster, PN Troso-Sandoval, T Rosen, N Rifkind, R Marks, PA Richon, VM
Citation: Pn. Munster et al., The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells, CANCER RES, 61(23), 2001, pp. 8492-8497
Role of taxanes in adjuvant therapy
Authors: Munster, PN Hudis, CA
Citation: Pn. Munster et Ca. Hudis, Role of taxanes in adjuvant therapy, CANCER INV, 18(1), 2000, pp. 32-38
Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer
Authors: Munster, PN Buzdar, A Dhingra, K Enas, N Ni, L Major, M Melemed, A Seidman, A Booser, D Theriault, R Norton, L Hudis, C
Citation: Pn. Munster et al., Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer, J CL ONCOL, 19(7), 2000, pp. 2002-2009
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
Authors: Zheng, FF Kuduk, SD Chiosis, G Munster, PN Sepp-Lorenzino, L Danishefsky, SJ Rosen, N
Citation: Ff. Zheng et al., Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases, CANCER RES, 60(8), 2000, pp. 2090-2094
Adjuvant therapy for resectable breast cancer
Authors: Munster, PN Hudis, CA
Citation: Pn. Munster et Ca. Hudis, Adjuvant therapy for resectable breast cancer, HEMAT ONCOL, 13(2), 1999, pp. 391
High-dose therapy for breast cancer
Authors: Hudis, CA Munster, PN
Citation: Ca. Hudis et Pn. Munster, High-dose therapy for breast cancer, SEMIN ONCOL, 26(1), 1999, pp. 35-47
Risultati: 1-9 |